Pfizer’s Lipitor Losing U.K. Patent Protection, the Times Says

Pfizer Inc. (PFE)’s Lipitor, the cholesterol pill that generated about $10.7 billion in sales for the world’s biggest drug maker in 2011, loses patent protection in the U.K. this weekend, the Times reported.

Generic drugs companies can begin to copy the New York- based company’s recipe for the tablet from tomorrow, the Times said, without saying where it got the information. Lipitor lost marketing exclusivity in the U.S. in November and Pfizer reported this month that first-quarter profit fell 19 percent after revenue from the drug declined because of generic competition.

To contact the reporter on this story: Neil Callanan in London at ncallanan@bloomberg.net

To contact the editor responsible for this story: Andrew Blackman at ablackman@bloomberg.net.

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.